Trial reportJournal of perinatology : official journal of the California Perinatal Association2026
Oral doxapram for apnea of prematurity: A randomized dosage trial.
Trial report in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the feasibility of oral doxapram dosing in very preterm infants. STUDY
designPhase-two, open-label randomized trial (ACTRN12621001163897) of two oral doxapram regimens for ≥5 days: higher-dose 48 mg/kg, then 24 mg/kg/6 h vs. lower-dose 24 mg/kg, then 12 mg/kg/6 h. Eligibility: born <32 weeks; CPAP ≥8 cmH PRIMARY OUTCOME: steady-state doxapram concentration in therapeutic range 1.5-4.0 mg/L, 2-4 h after 4-5
results2/16 (13%) infants in the higher-dose and 7/15 (47%) in the lower-dose group achieved steady state doxapram plasma concentrations in therapeutic range. Most infants (88%) in the higher-dose group had concentrations above therapeutic range. By day 5, oral doxapram increased mean SpO
conclusionOral doxapram is feasible in very preterm infants with improvements in oxygenation and ventilation. Lower doses (12 mg/kg/6 h) are sufficient in most infants.
Indexed as
Identifiers
41193649What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.